Straits Times Index
3,303.19 +10.26 (+0.31%) S&P 500
5,127.79 +63.59 (+1.26%) Dow
38,675.68 +449.98 (+1.18%) Nasdaq
16,156.33 +315.33 (+1.99%) Bitcoin USD
63,583.34 -161.64 (-0.25%) CMC Crypto 200
1,375.64 +63.02 (+4.80%)
Day One Biopharmaceuticals, Inc. (DAWN)
Pre-market:
| Previous close | 17.57 |
| Open | 18.00 |
| Bid | 17.10 x 200 |
| Ask | 17.20 x 800 |
| Day's range | 17.13 - 18.00 |
| 52-week range | 9.67 - 18.07 |
| Volume | |
| Avg. volume | 1,053,496 |
| Market cap | 1.5B |
| Beta (5Y monthly) | -1.48 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.37 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 36.63 |
GuruFocus.comInsider Sale at Day One Biopharmaceuticals Inc (DAWN)
York Charles N II, the COO, CFO, and Secretary of Day One Biopharmaceuticals Inc (NASDAQ:DAWN), sold 60,461 shares of the company on May 3, 2024.
GlobeNewswireDay One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation RAPNO LGG overall response rate (ORR) of 51% Day One receives rare pediatric disease priority review voucher Conference call and webcast to be April 24, 8:30 a.m. Eastern Time BRISBANE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a commercial-stage biopharmaceuti
Simply Wall St.Companies Like Day One Biopharmaceuticals (NASDAQ:DAWN) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
